Ilseung J. Choi

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

Journal: International journal of hematology

Published: March 18, 2026

Prognostic impact of morphological lymphocyte counts on aggressive adult T-cell leukemia/lymphoma: Japan ATL nationwide registry analysis.

Prognostic impact of morphological lymphocyte counts on aggressive adult T-cell leukemia/lymphoma: Japan ATL nationwide registry analysis.

Journal: Blood cancer journal

Published: February 08, 2026

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Journal: Blood cancer journal

Published: January 28, 2026

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.

Journal: Annals of hematology

Published: January 13, 2026

Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.

Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.

Journal: Cancer

Published: December 23, 2025

Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial.

Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial.

Journal: Cancer science

Published: October 12, 2025

Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Efficacy and Safety of Rituximab plus Modified EPOCH (Etoposide, Vincristine, Doxorubicin, Carboplatin, and Prednisolone) for Transplant-ineligible Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Journal: Internal medicine (Tokyo, Japan)

Published: April 13, 2025

A Multicenter Real-World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30-Positive Adult T-Cell Leukemia-Lymphoma.

A Multicenter Real-World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30-Positive Adult T-Cell Leukemia-Lymphoma.

Journal: Hematological oncology

Published: March 14, 2025

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.

Journal: Blood advances

Published: February 18, 2025

Clinical Significance of Elevated Levels of Soluble-Form Immune Checkpoint Molecules in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma.

Clinical Significance of Elevated Levels of Soluble-Form Immune Checkpoint Molecules in Patients With Aggressive Adult T-Cell Leukemia-Lymphoma.

Journal: EJHaem

Published: January 24, 2025

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma.

A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma.

Journal: Blood

Published: December 24, 2024

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Journal: Blood cancer journal

Published: September 05, 2024

Showing 1-12 of 109

Last Updated: 09/26/2026